• Molecular Pathology and Biology of Urothelial Cancer | Francisco X. Real, MD, PhD

• Optimal Management for NMIBC and MIBC Patients | Félix Guerrero-Ramos, MD, PhD, FEBU; Natalia Carballo, MD

• Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer | Enrique Grande, MD, MSc, PhD

This activity is designed for medical oncologists and urologists involved or interested in the management of urothelial cancer.

The aim of this educational activity is for participants to:

• • Develop a greater awareness of the different molecular and pathologic subtypes of urothelial cancers and the role of prognostic and predictive biomarkers in patient management
  • Appreciate the current and evolving treatment options for non-muscle-invasive bladder cancer (NMIBC)
  • Become familiar with the indications and limitations of local treatments for MIBC
  • Establish confidence and expertise in the selection and timing of systemic treatment options throughout the clinical course of locally advanced and metastatic urothelial cancers
  • Improve the understanding of emerging therapies and treatment combinations that are currently being developed for UC

This educational activity is provided by ACE Oncology.

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Enrique Grande has received honoraria for speaker engagements, advisory roles or funding for continuing medical education from Advanced Accelerator Applications, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Dr. Reddy’s, Eisai, Esteve, Eusa Pharma, Genetracer, GSK, Guardant Health, HRAPharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Raffo, Roche, Sanofi-Genzyme, Servier, Taiho, Tecnofarma, Thermo Fisher Scientific and Zodiac. He has also received grants for clinical research from Astellas, Astra Zeneca, IPSEN, Lexicon, Merck KGaA, MTEM/Threshold/Tersera, Nanostring Technologies, Pfizer and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Félix Guerrero-Ramos has served as an advisor or consultant for Pfizer, BMS, AstraZeneca, Janssen and Combat Medical. He has also served as a speaker or a member of a speakers bureau for Astellas Oncology, Janssen, Pfizer, AstraZeneca, Combat Medical and Nucleix. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Francisco X. Real has received grants for research from VCN Biosciences and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Natalia Carballo has no financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of ACE Oncology have disclosed no relevant financial relationships.

ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.